NCT05011019 - A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions

Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors

Interventions

DRUG

AL2846 capsules

AL2846 is a multi-target receptor tyrosine kinase inhibitor.

Trial Locations (1)

Shanghai Ninth People's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai